Evidence suggests a transcriptional regulation of the antigen presentation machinery, as genetic alterations in antigen presentation (B2M, HLA-A) and IFNγ signaling (IFNGR, STAT1 and JAK1/2) (16, 88) remain infrequent in melanomas and are not restricted to non-responding patients (89). The gene discussed is B2M; the disease is melanoma.